Summary

According to the recently published report ’Cholesteryl Ester Transfer Protein - Drugs In Development, 2021’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report ’Cholesteryl Ester Transfer Protein - Drugs In Development, 2021’ outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders and Infectious Disease which include indications Dyslipidemia, Acute Coronary Syndrome, Cardiovascular Disease and Coronavirus Disease 2019 (COVID-19).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope